Critical Considerations for Mergers & Acquisitions -
legal and regulatory overview on due diligence

March 18, 2021 | 03:00 PM CET


Summary

**For more information, please see PharmaLex Privacy Policy and VWV Privacy Statement

If you do not wish to receive any communication from us, you may unsubscribe at any time.

2021 started with stellar news as Sanofi agreed to acquire British biotech Kymab for around $1.45 billion. It is a chequered flag for the start of this seasons M&A activity for Life Sciences companies. Great expectations? This fast-growing sector comprises pharma, biotech, cell & gene therapy, medical device and diagnostics amongst all. Corporations must take expert legal and regulatory advice in addition to financial due diligence.

PharmaLex and VWV  ponder legal and regulatory solutions for supporting M&A deals, takeovers, business moves, leveraging, spin-outs, carve-outs and strategic partnerships.
 


Why Attend

KEY LEARNINGS
 

  •  Discover just when to involve legal and regulatory experts in an M&A process
  •  Good appreciation of the roles played by dedicated legal, regulatory and quality experts in M&A
  •  Be made aware of critical considerations around the pivot point: Due Diligence
  •  Hear about the 6th stage of M&A -Rescue, too often forgotten
speakers

Inspirational speakers from across the globe.

John Cahill

Director, Senior Consultant, Q&C
PharmaLex 

John has over 20 years’ experience working in a variety of technical and senior leadership roles including Quality Director, Production Director, MS&T projects and specialist roles at both national and international sites. His leadership experience brings strong capabilities in implementing best-in-class strategies in Operational Quality and Quality Systems.

Richard Phillips

Partner & Corporate Lawyer
VWV

Richard specializes in transactional and non-transactional corporate law. The majority of his work is in M&A. Through his 25 years of acting for a range of businesses from start-up and owner managed entities through to significant SMEs and listed companies, Richard has a depth of commercial experience which enables him to provide proactive and practical advice to his clients. He has been advising a number of senior decision making clients over many years and enjoys the strong 'trusted advisor' relationships that he has developed.
Richard is a regular participant in PING, the Pharmaceutical Industry Network Group run by VWV and has a number of clients in the Pharma and Life Sciences sector and in EMIG, the industry body and interest group for SME pharmaceutical companies.

Anna Geist

Director, Head of Regulatory & Special Projects
PharmaLex

Anna is a biologist with over fifteen years Regulatory Affairs experience in a global R&D environment and Regulatory Consultancy with a successful track record in overseeing the delivery of large-scale projects. As Head of Regulatory M&A Services at PharmaLex she is supporting mid-sized and large local and global MAH transfer programs, including strategic consultancy, MA transfer plan development and later on managing the specific MA transfer related activities per country / region by steering successfully through all transfer phases and involving all stakeholders and parties.